Recent events
Recent events tied to this brand in public sources.
Back to profile5 entries
2026
XtalPi and Dongyangguang Pharmaceutical sign strategic cooperation to form joint venture
XtalPi Holdings signed a strategic cooperation agreement with Dongyangguang Pharmaceutical; the two parties plan to establish a joint venture company and jointly build an AI plus robotics joint laboratory and a non-clinical drug large model, carrying out cooperation on underlying technology, new drug pipeline development and commercialization. Dongyangguang Pharmaceutical is expected to invest several hundred million yuan, with the two companies aiming to build an industry-leading AI drug R&D engine and achieve technology going global.
2020
Dongyangguang Pharma receives Hong Kong listing approval for H shares
Dongyangguang Pharma received approval from the Hong Kong Stock Exchange on August 18 for 226,200,000 H shares to be listed and traded. The related share conversion and listing procedures were not yet complete.
2020
China Resources Pharmaceutical Commercial and Dongyangguang Pharmaceutical sign strategic cooperation agreements
China Resources Pharmaceutical Commercial and Dongyangguang Pharmaceutical signed strategic and e-commerce strategic cooperation agreements recently. The cooperation is intended to provide medicine services to medicine terminals and patients nationwide through the internet.
2019
Dongyangguang adjusts proposed drug-rights acquisition price
Dongyangguang announced that its subsidiary Dongyangguang Pharmaceutical had adjusted the proposed acquisition price for the China rights to two diabetes drugs from RMB 2.057 billion to RMB 1.6456 billion.
2019
Dongyangguang Pharmaceutical proposes acquiring two diabetes drugs
Dongyangguang Pharmaceutical proposed acquiring the rights to two diabetes drugs, jiaoguangsu ronggeliejing and liraglutide, for 2.057 billion yuan to expand its product pipeline.